Compare NTLA & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | AIN |
|---|---|---|
| Founded | 2014 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2016 | 1994 |
| Metric | NTLA | AIN |
|---|---|---|
| Price | $11.36 | $66.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 3 |
| Target Price | $23.11 | ★ $69.00 |
| AVG Volume (30 Days) | ★ 4.9M | 240.0K |
| Earning Date | 11-17-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 2.60 |
| Revenue | $67,671,000.00 | ★ $1,054,132,000.00 |
| Revenue This Year | N/A | $11.29 |
| Revenue Next Year | $143.36 | $5.61 |
| P/E Ratio | ★ N/A | $27.70 |
| Revenue Growth | ★ 16.92 | 7.29 |
| 52 Week Low | $7.95 | $41.15 |
| 52 Week High | $18.48 | $77.00 |
| Indicator | NTLA | AIN |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 72.05 |
| Support Level | $11.26 | $70.54 |
| Resistance Level | $13.50 | $72.85 |
| Average True Range (ATR) | 0.81 | 2.42 |
| MACD | 0.05 | 1.18 |
| Stochastic Oscillator | 51.49 | 75.58 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Albany International Corp is a textiles and materials processing company specializing in engineered fabrics and composite components and assemblies for the paper, industrial manufacturing and aerospace industries. It operates through two segments: Machine Clothing, which produces custom-designed fabrics and high-speed process belts for paper, paperboard, tissue, towel and pulp, as well as engineered fabrics for other industrial applications, and contributes the majority of revenue; and Albany Engineered Composites, which provides engineered composite parts for the aerospace and defense industries. The company generates revenue from the United States, Switzerland, Brazil, China, Mexico, France and other areas.